Comparison of choroidal thickness changes following intravitreal dexamethasone, ranibizumab, and triamcinolone in eyes with retinal vein occlusion

Basit Öğe Kaydı
dc.contributor.authorYumusak, Erhan
dc.contributor.authorOrnek, Kemal
dc.contributor.authorDikel, Nevin H.
dc.date.accessioned2020-06-25T18:16:04Z
dc.date.available2020-06-25T18:16:04Z
dc.date.issued2016
dc.departmentKırıkkale Üniversitesi
dc.description.abstractPurpose: To evaluate short-term choroidal thickness changes following intravitreal dexamethasone implant (DEX), ranibizumab (RAN), and triamcinolone acetonide (TA) in eyes with retinal vein occlusion (RVO) and macular edema (ME). Methods: In this prospective study, 35 eyes of 35 patients with RVO and ME who were treated with intravitreal injections of DEX, RAN, and TA were included. Choroidal thickness was measured using semiautomated segmentation of enhanced depth imaging with optical coherence tomography at fovea and parafoveal areas. Changes in choroidal thickness following treatment were compared statistically. Results: Choroidal thickness decreased following DEX, RAN, and TA treatments (all p>0.05). In the DEX group, at the first month nasal 1,500 mu m (N1(1,500)) and at the third month subfoveal (SF3) and nasal 500 mu m (N3(500)) choroidal thickness revealed a significant reduction compared to RAN and TA groups (all p<0.05). In the TA group, choroidal thickness showed a significant reduction only at nasal 1,500 mu m (N3(1,500)) at the third month (p<0.05). Conclusions: Choroidal thickness was decreased in all 3 groups. The DEX and TA groups showed a significant reduction at some areas. Ranibizumab had the smallest effect on choroidal thickness after 3 months among all groups.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.5301/ejo.5000734
dc.identifier.endpage632en_US
dc.identifier.issn1120-6721
dc.identifier.issn1724-6016
dc.identifier.issue6en_US
dc.identifier.pmid26847213
dc.identifier.scopus2-s2.0-84994494813
dc.identifier.scopusqualityQ2
dc.identifier.startpage627en_US
dc.identifier.urihttps://doi.org/10.5301/ejo.5000734
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6405
dc.identifier.volume26en_US
dc.identifier.wosWOS:000393691000031
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltden_US
dc.relation.ispartofEuropean Journal Of Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChoroidal thicknessen_US
dc.subjectDexamethasoneen_US
dc.subjectIntravitrealen_US
dc.subjectRanibizumaben_US
dc.subjectRetinal vein occlusionen_US
dc.subjectTriamcinoloneen_US
dc.titleComparison of choroidal thickness changes following intravitreal dexamethasone, ranibizumab, and triamcinolone in eyes with retinal vein occlusionen_US
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu